ISSN: 2451-0637
Archives of Medical Science - Civilization Diseases
Current volume Archive About the journal Abstracting and indexing Contact Instructions for authors Ethical standards and procedures

1/2021
vol. 6
 
Share:
Share:
more
 
 
abstract:
Experimental research

Comparative study of the efficacy of bevacizumab and rose bengal photodynamic therapy for treatment of corneal neovascularization

Aziza Ahmed
1
,
Salwa Abdelkawi
2
,
Mohamed Elgohary
3
,
Ayman Elshinawy
3
,
Dina Fouad
1

1.
Ophthalmic Unit, National Institute of Laser Enhanced Sciences, Cairo University, Egypt
2.
Department of Vision Science, Biophysics and Laser Science Unit, Research Institute of Ophthalmology, Giza, Egypt
3.
Physics Department, Biophysics Branch, Faculty of Science, Al-Azhar University (Boys), Cairo, Egypt
Arch Med Sci Civil Dis 2021; 6: e22–e30
Online publish date: 2021/05/05
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
To compare the efficacy of bevacizumab and rose bengal photodynamic therapy (RB-PDT) in the treatment of corneal neovascularization (CNV).

Material and methods
The study design included the induction of CNV by suture placement in three groups of New Zealand rabbits: (1) a group with CNV without any treatment; (2) a group treated with subconjunctival injection of bevacizumab (25 mg/eye); (3) a group treated with intravenous injection of rose bengal and exposed to 532 nm photodynamic therapy. For 4 weeks, the animals were followed up by slit-lamp to analyze the extent of CNV, evaluate the corneal protein secondary structure, and determine the oxidative stress index (OSI).

Results
After 4 weeks, traces of neovascularization were observed only in the bevacizumab treated group with grade 0.5. The contents of -helix and -sheet were 17% and 61% in CNV, 32%, and 46% in bevacizumab and 40% and 36% in RB-PDT groups vs. 43% and 35% for the control group. Moreover, the percentage changes in the total oxidative status (TOS) for CNV, bevacizumab and RB-PDT groups were 97.1%, 14.6%, and 1.0%, respectively, with respect to the control. The total antioxidant status (TAC) showed no significant changes (p > 0.05) for both treated groups. The percentage of changes in OSI was 15.9% and 1.3% in bevacizumab, and RB-PDT treated groups compared with the control group.

Conclusions
Both modes of treatment were effective in the regression of CNV, but RB-PDT was more efficient than bevacizumab by improving the corneal protein secondary structure and the oxidative stress.

keywords:

corneal neovascularization, bevacizumab, photodynamic therapy, protein secondary structure, oxidative stress

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe